Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DVAX Stock Forecast 2025-2026
$10.89
Current Price
$1.28B
Market Cap
Buy 3
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to DVAX Price Targets
+129.6%
To High Target of $25.00
+88.2%
To Median Target of $20.50
+1.0%
To Low Target of $11.00
DVAX Price Momentum
+1.7%
1 Week Change
+0.6%
1 Month Change
-15.3%
1 Year Change
-14.7%
Year-to-Date Change
-25.6%
From 52W High of $14.63
+18.4%
From 52W Low of $9.20
📊 TOP ANALYST CALLS
Did DVAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dynavax is one of their latest high-conviction picks.
Latest DVAX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, DVAX has a bullish consensus with a median price target of $20.50 (ranging from $11.00 to $25.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $10.89, the median forecast implies a 88.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Roy Buchanan at JMP Securities, projecting a 129.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DVAX Analyst Ratings
3
Buy
0
Hold
1
Sell
DVAX Price Target Range
Low
$11.00
Average
$20.50
High
$25.00
Current: $10.89
Latest DVAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DVAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 22, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $32.00 |
| Aug 8, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $32.00 |
| May 7, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $31.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Sell | Maintains | $10.00 |
| Feb 21, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Maintains | $33.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $31.00 |
| Feb 11, 2025 | Goldman Sachs | Paul Choi | Sell | Downgrade | $12.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $31.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Aug 8, 2024 | Goldman Sachs | Paul Choi | Neutral | Maintains | $15.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| May 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| May 9, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Feb 1, 2024 | Goldman Sachs | Paul Choi | Neutral | Initiates | $20.00 |
| Nov 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $28.00 |
| Nov 3, 2023 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $27.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $27.00 |
| Aug 4, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $25.00 |
Dynavax Technologies Corporation (DVAX) Competitors
The following stocks are similar to Dynavax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dynavax Technologies Corporation (DVAX) Financial Data
Dynavax Technologies Corporation has a market capitalization of $1.28B with a P/E ratio of 54.6x. The company generates $330.51M in trailing twelve-month revenue with a -13.1% profit margin.
Revenue growth is +17.7% quarter-over-quarter, while maintaining an operating margin of +24.8% and return on equity of -7.1%.
Valuation Metrics
Market Cap
$1.28B
Enterprise Value
$920.17M
P/E Ratio
54.6x
PEG Ratio
0.7x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
+17.7%
Gross Margin
+84.8%
Operating Margin
+24.8%
Net Margin
-13.1%
EPS Growth
+53.0%
Financial Health
Cash/Price Ratio
+50.7%
Current Ratio
7.6x
Debt/Equity
54.1x
ROE
-7.1%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dynavax Technologies Corporation (DVAX) Business Model
About Dynavax Technologies Corporation
What They Do
Develops vaccines and immunotherapy for diseases.
Business Model
Dynavax Technologies Corporation generates revenue through the development and commercialization of vaccines, including its FDA-approved hepatitis B vaccine, HEPLISAV-B. The company leverages advanced immunology technologies to create innovative vaccination solutions, enhancing immune responses and addressing public health needs.
Additional Information
With a focus on improving vaccine efficacy through adjuvant technologies like CpG 1018, Dynavax aims to meet unmet healthcare demands. Headquartered in Emeryville, California, the company is positioned to play a vital role in the biopharmaceutical industry and contribute to global health initiatives.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
405
CEO
Mr. Ryan Spencer
Country
United States
IPO Year
2004
Website
www.dynavax.comDynavax Technologies Corporation (DVAX) Latest News & Analysis
Latest News
Quick Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in a fireside chat at the Evercore Healthcare Conference on December 2, 2025, at 2:10 p.m.
Why It Matters
Dynavax's participation in a prominent healthcare conference may indicate upcoming developments or insights that could influence investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Dynavax Technologies (DVAX) will hold its Q3 2025 earnings call on November 5, 2025, at 4:30 PM EST, featuring key executives and analysts from various financial institutions.
Why It Matters
Dynavax's earnings call highlights its financial health and strategic direction, influencing investor sentiment and stock performance based on growth prospects and market positioning.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Dynavax Technologies (DVAX) reported Q3 earnings of $0.21 per share, surpassing estimates of $0.14. This is an increase from $0.12 per share in the same quarter last year.
Why It Matters
Dynavax's earnings beat expectations and show year-over-year growth, indicating strong performance and potential for future profitability, which can positively influence investor sentiment and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
1 month ago
Quick Summary
HEPLISAV-B® reported Q3 net product revenue of $90 million, up 13% YoY. Full-year 2025 revenue guidance is $315-$325 million. A $100 million share repurchase program was authorized. They also entered a licensing agreement for a COVID-19 vaccine.
Why It Matters
HEPLISAV-B's revenue growth and guidance signals strong product demand. A new share repurchase program may boost stock value, while expansion into vaccines enhances growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
1 month ago
Quick Summary
Vaxart and Dynavax are collaborating on an oral COVID-19 vaccine. Vaxart will lead Phase 2b development, while Dynavax gains exclusive rights post-phase and pays $25M upfront, plus $5M equity.
Why It Matters
The collaboration enhances Vaxart's funding and development capabilities while providing Dynavax with potential revenue streams, signaling a strategic partnership that may boost both companies' market valuations.
Source: PRNewsWire
Market Sentiment:
Neutral
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
1 month ago
Quick Summary
Dynavax Technologies (Nasdaq: DVAX) will release its Q3 2025 financial results on November 5, 2025, after U.S. market close.
Why It Matters
Dynavax's upcoming financial results could impact stock performance, reflecting its revenue growth and market position in the biopharmaceutical sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DVAX Stock
What is Dynavax Technologies Corporation's (DVAX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Dynavax Technologies Corporation (DVAX) has a median price target of $20.50. The highest price target is $25.00 and the lowest is $11.00.
Is DVAX stock a good investment in 2026?
According to current analyst ratings, DVAX has 3 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $10.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DVAX stock?
Wall Street analysts predict DVAX stock could reach $20.50 in the next 12 months. This represents a 88.2% increase from the current price of $10.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dynavax Technologies Corporation's business model?
Dynavax Technologies Corporation generates revenue through the development and commercialization of vaccines, including its FDA-approved hepatitis B vaccine, HEPLISAV-B. The company leverages advanced immunology technologies to create innovative vaccination solutions, enhancing immune responses and addressing public health needs.
What is the highest forecasted price for DVAX Dynavax Technologies Corporation?
The highest price target for DVAX is $25.00 from Roy Buchanan at JMP Securities, which represents a 129.6% increase from the current price of $10.89.
What is the lowest forecasted price for DVAX Dynavax Technologies Corporation?
The lowest price target for DVAX is $11.00 from at , which represents a 1.0% increase from the current price of $10.89.
What is the overall DVAX consensus from analysts for Dynavax Technologies Corporation?
The overall analyst consensus for DVAX is bullish. Out of 9 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $20.50.
How accurate are DVAX stock price projections?
Stock price projections, including those for Dynavax Technologies Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 10:34 AM UTC